Motion Sickness
📧 Sign up to get email alerts when something new happens for Motion Sickness.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-31Clinical Trial Update: Gynecologic Endoscopic Surgery of Female Motion Sickness Patients [Phase 4]
Phase 4 clinical trial update related to gynecologic endoscopic surgery in motion sickness patients, completed.
-
FDA label_change · 2023-12-27FDA Approved: PROMETHAZINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Promethazine hydrochloride from Hikma Pharmaceuticals USA, authorizing changes to the product la…
-
FDA approval · 2023-10-27FDA Approved: SCOPOLAMINE TRANSDERMAL SYSTEM — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for Scopolamine Transdermal System submitted by Padagis Israel Pharmaceuticals Ltd.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Non-pharmaceutical Motion Sickness Mitigation [NA]
Clinical trial update for non-pharmaceutical motion sickness mitigation; study completed with results posted.
-
FDA approval · 2023-09-22FDA Approved: MECLIZINE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Meclizine hydrochloride from Amneal Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects [Phase 3]
Phase 3 trial evaluating prevention and treatment of nausea associated with motion sickness in senior subjects has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion [Phase 3]
Phase 3 trial update on DPI-386 nasal gel for prevention of nausea and vomiting due to motion; study completed.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Sensory Training for Visual Motion Sickness [NA]
Completed clinical trial evaluating sensory training for dizziness and vertigo with related motion sickness; results posted in 2023.
-
FDA approval · 2022-11-02FDA Approved: PROMETHAZINE HYDROCHLORIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' generic promethazine hydrochloride under an original ANDA. The approval authorizes marketing of the gen…
-
FDA approval · 2022-08-11FDA Approved: MECLIZINE HYDROCHLORIDE — Original Application (Chartwell RX, LLC)
The FDA approved an original ANDA for Meclizine hydrochloride from Chartwell RX, LLC, establishing a generic product. Meclizine hydrochlorid…
-
FDA approval · 2021-09-28FDA Approved: PROCHLORPERAZINE EDISYLATE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approves Cosette Pharmaceuticals' prochlorperazine edisylate as an original generic application for use as an antiemetic.
-
CLINICAL_TRIALS trial_result · 2021-09-17Clinical Trial Update: Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion [Phase 3]
A Phase 3 trial evaluating a nasal gel to prevent nausea and vomiting associated with motion has completed.
-
FDA approval · 2021-07-12FDA Approved: PROMETHAZINE HYDROCHLORIDE — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved promethazine hydrochloride under an original ANDA for Quagen Pharmaceuticals LLC.
-
FDA approval · 2020-06-23FDA Approved: MECLIZINE HYDROCHLORIDE — Original Application (Zydus Lifesciences Limited)
FDA approved a generic meclizine hydrochloride product from Zydus Lifesciences Limited (ANDA213957), expanding treatment options for motion …
-
FDA approval · 2020-03-17FDA Approved: DIPHENHYDRAMINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for Diphenhydramine hydrochloride from PAI Pharma, indicating an approved modification to an existin…
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness [Phase 3]
Phase 3 trial update on a nasal gel intended to prevent nausea from motion sickness under military operational conditions.
-
CLINICAL_TRIALS trial_result · 2020-01-07Clinical Trial Update: DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness [Phase 2, Phase 3]
Clinical trial update for DPI 386 nasal gel in prevention of nausea due to motion sickness; study phases 2 and 3 have been terminated.
-
FDA approval · 2019-12-23FDA Approved: MECLIZINE HYDROCHLORIDE — Supplemental Application (Epic Pharma LLC)
The FDA approved a supplemental application for Meclizine hydrochloride from Epic Pharma LLC, indicating regulatory action on an already-app…
-
FDA approval · 2019-12-05FDA Approved: MECLIZINE HYDROCHLORIDE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approved a supplemental application for Meclizine hydrochloride from Jubilant Cadista Pharmaceuticals Inc., authorizing an updated gener…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness [Phase 3]
Phase 3 clinical trial update for a nasal gel aimed at prevention and treatment of nausea associated with motion sickness.
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: The Prevention and Treatment of Nausea Associated With Motion Sickness [Phase 3]
Phase 3 clinical trial update for prevention and treatment of nausea associated with motion sickness has completed.
-
CLINICAL_TRIALS trial_result · 2019-09-25Clinical Trial Update: Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness [Phase 4]
Phase 4 trial evaluating ginger extract for motion sickness has been completed.
-
FDA approval · 2019-06-28FDA Approved: MECLIZINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Meclizine Hydrochloride from Rising Pharma Holdings, Inc., updating the product's labeling/indic…
-
FDA approval · 2019-06-19FDA Approved: SCOPOLAMINE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original Abbreviated New Drug Application for scopolamine, enabling a generic version of the product.
-
CLINICAL_TRIALS trial_result · 2019-04-19Clinical Trial Update: Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels [Phase 3]
Phase 3 study evaluating DPI-386 nasal gel for prevention and treatment of nausea associated with motion sickness; current status is unknown…